A novel mucin-sulphatase activity found in Burkholderia cepacia and Pseudomonas aeruginosa

Journal of Medical Microbiology

Volumn 48, Issue 6, 1999, Pages 551-557

  Jansen, Hugo Jan ^a   Hart, C Anthony ^a,c   Rhodes, Jonathan M ^b   Saunders, Jonathan R ^a   Smalley, John W ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLSULFATASE; BACTERIAL ENZYME; MUCIN; SULFATASE; SULFUR 35;

ARTICLE; BACTERIAL INFECTION; BURKHOLDERIA CEPACIA; CELL LINE; COLON CARCINOMA; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; LUNG INFECTION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0032855883     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-48-6-551     Document Type: Article

References (54)

1. 1. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Psuedomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60: 539-574.
2. 2. Govan JRW, Hughes JE, Vandamme P. Burkholderia cepacia: medical, taxonomic and ecological issues, J Med Microbiol 1996; 45: 395-407.
3. 3. Cheng K, Smyth RL, Govan JRW et al. Spread of a β-lactam resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996; 348: 639-642.
4. 4. Govan JRW, Brown PH, Maddison J et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993; 342: 15-19.
5. + Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nature Med 1995; 1: 661-666.
6. 6. Chace KV, Leahy DS, Martin R, Carubelli R, Flux M, Sachdev GP. Respiratory mucous secretions in patients with cystic fibrosis: relationship between levels of highly sulfated mucin component and severity of the disease. Clin Chim Acta 1983; 132: 143-155.
7. 7. Chace KV, Flux M, Sachdev GP. Comparison of physicochemical properties of purified mucus glycoproteins isolated from respiratory secretions of cystic fibrosis and asthmatic patients. Biochemistry 1985; 24: 7334-7341.
8. 8. Cheng PW, Boat TF, Cranfill K, Yankaskas JR. Boucher RC. Increased sulfation of glycoconjugates by cultured nasal epithelial cells from patients with cystic fibrosis. J Clin Invest 1989; 84: 68-72.
9. 9. Mohapatra NK, Cheng P-W, Parker JC et al. Alteration of sulfation of glycoconjugates, but not sulfate transport and intracellular inorganic sulfate content in cystic fibrosis airway epithelial cells. Pediatr Res 1995; 38: 42-48.
10. 10. Houdret N, Ramphal R, Scharfman A et al. Evidence for the in vivo degradation of human respiratory mucins during Pseudomonas aeruginosa infection. Biochim Biophys Acta 1989; 992: 96-105.
11. 11. Strous GJ, Dekker J. Mucin-type glycoproteins. Crit Rev Biochem Mol Biol 1992; 27: 57-92.
12. 12. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85: 229-236.
13. 13. Roberton AM, Wright DP. Bacterial glycosulphatases and sulphomucin degradation. Can J Gastroenterol 1997; 11: 361-366.
14. 14. Tsai HH, Hart CA, Rhodes JM. Production of mucin degrading sulphatase and glycosidases by Bacteroides thetaiotaomicron. Leu Appl Microbiol 1991; 13: 97-101.
15. 15. Bradshaw DJ, Homer KA, Marsh PD, Beighton D. Metabolic cooperation in oral microbial communities during growth on mucin. Microbiology 1994; 140: 3407-3412.
16. 16. Van der Hoeven JS, Camp PJM. Synergistic degradation of mucin by Streptococcus oralis and Streptococcus sanguis in mixed chemostat cultures. J Dent Res 1991; 70: 1041-1044.
17. 17. Hoskins LC. Human enteric population ecology and degradation of gut mucins. Dig Dis Sci 1981; 26: 769-772.
18. 18. Willis CL, Cummings JH, Neale G, Gibson GR. In vitro effects of mucin fermentation on the growth of human colonic sulphate-reducing bacteria. Anaerobe 1996; 2: 117-122.
19. 19. Capon C, Laboisse CL, Wieruszeski J-M, Maoret J-J, Augeron C, Fournet B. Oligosaccharide structures of mucins secreted by the human colonic cancer cell line CL.16E. J Biol Chem 1992; 267: 19248-19257.
20. (a+b-)) patient suffering from chronic bronchitis. Glycoconj J 1997; 14: 113-125.
21. 21. Lo-Guidice J-M, Wieruszcski J-M, Lemoine J, Verbert A, Roussel P, Lamblin G. Sialylation and sulfation of the carbohydrate chains in respiratory mucins from a patient with cystic fibrosis. J Biol Chem 1994; 269: 18794-18813.
22. 22. Mawhinney TP, Adelstein E, Gayer DA, Landrum DC, Barbero GJ. Structural analysis of monosulfated side-chain oligosaccharides isolated from human trachcobronchial mucous glycoproteins. Carbohydr Res 1992; 223: 187-207.
23. 23. Sangadala S, Bhat UR, Mendicino J. Structures of sulfated oligosaccharides in human trachea mucin glycoproteins. Mol Cell Biochem 1993; 126: 37-47.
24. 24. Slomiany BL, Murty VLN, Slomiany A. Structural features of carbohydrate chains in human salivary mucins. Int J Biochem 1993; 25: 259-265.
25. 25. Wu AM, Csako G, Herp A. Structure, biosynthesis, and function of salivary mucins. Mol Cell Biochem 1994; 137: 39-55.
26. 26. Ramphal R, Carnoy C, Fievre S et al. Pseudomonas aeruginosa recognizes carbohydrate chains containing type 1 (Ga1β1-3G1cNAc) or type 2 (Ga1β1-4G1cNAc) disaccharide units. Infect Immun 1991; 59: 700-704.
27. 27. Sajjan US, Corey M, Karmali MA, Forstner JF. Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest 1992; 89: 648-656.
28. 28. Scharfman A, Van Brussel E, Houdret N, Lamblin G, Roussel P. Interactions between glycoconjugates from human respiratory airways and Pseudomonas aeruginosa. Am J Respir Crit Care Med 1996; 154: S163-S169.
29. 29. Butler SL, Doherty CJ, Hughes JE, Nelson JW, Govan JRW. Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? J Clin Microbiol 1995; 33: 1001-1004.
30. 30. Corkill JE, Sisson PR, Smyth A et al. Application of pyrolysis mass spectroscopy and SDS-PAGE in the study of the epidemiology of Pseudomonas cepacia in cystic fibrosis. J Med Microbiol 1994; 41: 106-111.
31. 31. Diaz S, Varki A. Metabolic radiolabeling of animal cell glycoconjugates. In: Coligan JE, Dunn BM, Ploegh HL, Speichler DW, Wingfield PT (eds) Current protocols in protein science, vol 1. New York, John Wiley and Sons. 1995: 12.2.1-12.2.15.
32. 32. Campbell BJ, Finnie TA, Hounsell EF, Rhodes JM. Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin. J Clin Invest 1995; 95: 571-576.
33. 33. Smalley JW, Dwarakanath D, Rhodes JM, Hart CA. Mucinsulphatase activity of some oral streptococci. Caries Rex 1994; 28: 416-420.
34. 34. Tsai HH, Sunderland D, Gibson GR, Hart CA, Rhodes JM. A novel mucin sulphatase from human faeces: its identification, purification and characterization. Clin Sci 1992; 82: 447-454.
35. 35. Bascomb S. Enzyme tests in bacterial identification. In: Colwell RR, Grigorova R (eds) Methods in microbiology, vol 19. Current methods for classification and indentitication of microorganisms. Academic Press. 1987: 105-160.
36. 36. Delisle GJ, Milazzo FH. The isolation of arylsulphatase isoenzymes from Pseudomonas aeruginosa. Biochim Biophys Acta 1970; 212: 505-508.
37. 37. Lucas JJ, Burchiel SW, Segel IH. Choline sulfatase of Pseudomonas aeruginosa. Arch Biochem Biophys 1972; 153: 664-672.
38. 38. Fitzgerald WJ, Knight LC. Physiological control of alkylsulfatase synthesis in Pseudomonas aeruginosa: effects of glucose, glucose analogs, and sulfur. Can J Microbiol 1977; 23: 1456-1464.
39. 39. Kuhns W, Jain RK, Matta KL et al. Characterization of a novel mucin sulphotransferase activity synthesising sulphated O-glycan core 1, 3-sulphate-Ga1β1-3Ga1NAcu-R. Glycobiology 1995; 5: 689-697.
40. 40. O'Brien M, Mitsuoka T. Quantitative fluorometric assay for rapid enzymatic characterization of Bifidobacterium longum and related bifidobacteria. Microbiol Immunol 1991; 35: 1041-1047.
41. 41. Roberton AM, McKenzie CG, Shafe N, Stubbs LB. A glycosulphatase that removes sulphate from mucus glycoprotein. Biochem J 1993; 239: 683-689.
42. 42. Van Klinken BJ-W, Tytgat KMAJ, Büller HA, Einerhand AWC, Dekker J. Biosynthesis of intestinal mucins: MUC1, MUC2, MUC3 and more. Biochem Soc Trans 1995; 23: 814-818.
43. 43. Porchet N, Pigny P, Buisine MP et al. Human mucin genes: genomic organization and expression of MUC4, MUC5AC and MUC5B. Biochem Soc Trans 1995; 23: 800-805.
44. 44. Gerken TA, Owens CL, Pasumarthy M. Determination of the site-specific O-glycosylation pattern of the porcine submaxillary mucin tandem repeat glycopeptide. J Biol Chem 1997; 272: 9709-9719.
45. 45. Hansen W, Yourassowsky E, [Detection of glycosidases in Pseudomonas of the fluorescent group: relation between serotype and giycosidase activities in P. aeruginosa,] Ann Microbiol 1983; 134B: 411-419.
46. 46. Forstner JF, Forstner GG. Gastrointestinal mucus. In: Johnson LR, Alpers DH, Jacobson ED, Christensen J, Walsh JH (eds) Physiology of the gastrointestinal tract, 3rd edn, vol 2. New York, Raven Press, 1994: 1255-1283.
47. 47. Sajjan U, Reisman J, Doig P, Irvin RT, Forstner G, Forstner J. Binding of nonmucoid Pseudomonas aeruginosa to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest 1992; 89: 657-665.
48. 48. Jansen HJ, Hart CA, Saunders JR, Rhodes JM, Smalley JW. Ural streptococcal mucin-sulphatase activity. J Dent Res 1997; 76: 1059.
49. 49. Murty VLN, Piotrowski J, Morita M, Slomiany A, Slomiany BL. Inhibition of Helicobacter pylori glycosulfatase activity toward gastric sulfomucin by nitecapone. Biochem Int 1992; 26: 1091-1099.
50. 50. Corfield AP, Wagner SA, Clamp JR. Kriaris MS, Hoskins LC. Mucin degradation in the human colon: production of sialidase, sialate-O-acctylesterase, N-acctylneuraminate lyase, arylesterase, and glycosulfatase activities by strains of faecal bacteria, Infect Immun 1992; 60: 3971-3978.
51. 51. Leprat R, Michel-Briand Y, Extracellular neuraminidase production by a strain of Pseudomonas aeruginosa isolated from cystic fibrosis. Ann Microbiol 1980; 131B: 209-222.
52. 52. Scharfman A, Ramphal R, Neut C, Carnoy C, Lamblin G, Roussel P. Arylneuraminidase activity of Pseudomonas aeruginosa does not degrade natural substrates such as human respiratory mucins. Infect Immun 1991; 59: 4283-4285.
53. 53. Carnoy C, Ramphal R, Scharfman A et al. Altered carbohydrate composition of salivary mucins from patients with cystic fibrosis and the adhesion of Pseudomonas aeruginosa. Am J Respir Cell Mol Biol 1993; 9; 323-334.
54. 54. Vavasseur F, Dole K, Yang J et al. O-glycan biosynthesis in human colorectal adenoma cells during progression to cancer, Eur J Biochem 1994; 222: 415-424.